



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kenji Fukudome and Charles T. Esmon

Serial No: 09/378,261

Art Unit: 1647

Filed: August 20, 1999

Examiner: S. Gucker

For: *Cloning and Regulation of an Endothelial Cell Protein C/
Activated Protein C Receptor*

TECH CENTER 1600/2900

JAN 16 2002

RECEIVED

#10
M.G.
1/16/02Assistant Commissioner
for Patents
Washington, D. C. 20231**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST
AND REVOCATION OF PRIOR POWERS**

Sir:

As owner of the entire interest of the above-identified patent application, all powers of attorney previously given are hereby revoked and the following attorneys and agents are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith:

Patrea L. Pabst
Zhaoyang Li
Rivka MonheitRegistration No. 31,284
Registration No. 46,872
Registration No. P-48,731

Please send all correspondence relating to the above-identified patent application to:

Patrea L. Pabst
HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, Suite 2000
Atlanta, Georgia 30309-3400(404) 817-8473 - Telephone
(404) 817-8588 - Telefax

U.S.S.N. 09/378,261
Filed August 20, 1999
Power of Attorney by Assignee of ENTIRE OR JOINT
Interest and Revocation of Prior Powers



The undersigned signatory (whose title is supplied below) is empowered to act on behalf of the assignee identified below, and has reviewed all the documents in the chain of title of the patent application and, to the best of undersigned's knowledge and belief, title is in the assignee.

OKLAHOMA MEDICAL RESEARCH FOUNDATION

TECH CENTER 1600/2900

JAN 16 2002

RECEIVED

By:

Name:


Title:

Harry L. Kennedy
Harry L. Kennedy
Director Technology Transfer

Date:

Aug 29, 2001

ATL1 #477060 v1



PTO/SB/98 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Kenji Fukudome and Charles T. EsmonApplication No./Patent No.: 09/378,261 Filed/Issue Date: August 20, 1999Entitled: Cloning and Regulation of an Endothelial Cell Protein C/Activated Protein C Receptor

Oklahoma Medical Research Foundation, a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Howard Hughes Medical Institute To: Oklahoma Medical Research Foundation
The document was recorded in the United States Patent and Trademark Office at Reel 010395, Frame 0871, or for which a copy thereof is attached.
2. From: Kenji Fukudome and Charles T. Esmon To: Oklahoma Medical Research Foundation
The document was recorded in the United States Patent and Trademark Office at Reel 7167, Frame 0985, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

[] Additional documents in the chain of title are listed on a supplemental sheet.

- [] Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Aug 29, 2001
Date

LARRY J. KENNEDY
Typed or printed name
[Signature]
Signature
Director Technology Transfer
Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JAN 16 2002

TECH CENTER 1600/2900

CALL 16547



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1>TRANSMITTAL FORM</h1> <p>(to be used for all correspondence after initial filing)</p>	Application Number	09/378,261
	Filing Date	August 20, 1999
	First Named Inventor	Kenji Fukudome
	Group Art Unit	1647
	Examiner Name	S. Gucker
Total Number of Pages in This Submission	Attorney Docket Number	OMRF 152 DIV (3)

TECH CENTER 1600/2900

JAN 16 2002

RECEIVED

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): Statement under 37 CFR 3.73(b); Return receipt postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Patrea L. Pabst Holland & Knight, LLP
Signature	
Date	October 16, 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <u>October 18, 2001</u>			
Typed or printed name	<u>Aisha Wyatt</u>		
Signature	<u>Aisha Wyatt</u>	Date	<u>October 18, 2001</u>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.